Eli Lilly and Co
Biogen’s Alzheimer’s drug could be more competitive than peers, Stifel says in upgrade to buy
Biogen ‘s new Alzheimer’s treatment could lead to even stronger gains for the biotech company going forward, according to Stifel. Analyst Paul Matteis upgraded shares of the biotech company to buy from hold, saying that upcoming data for Alzheimer treatments from competitors Roche and Eli Lilly could show that clinical results for Biogen’s product, lecanemab, […]
Read More
3 takeaways from our daily meeting: Wall Street’s bounce, small buy, reviewing analyst notes
The Investing Club holds its “Morning Meeting” every weekday at 10:20 a.m. ET. Source
Read More
3 takeaways from our daily meeting: Defensive stocks, trimming semis, Meta downgrade
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. The defensives are the only place to be Semis and U.S.-China tensions Quick mentions: META, STZ 1. The defensives are the only place to be Stocks edged down Tuesday, while […]
Read More
A series of mega-blockbuster drugs are on the horizon. How to invest in the trend
Biopharma companies are having more clinical success treating Alzheimer’s disease and obesity and are taking new approaches in oncology, and that’s creating more mega-blockbuster drugs, according to Bank of America. Analyst Geoff Meacham has identified 20 drugs that have the potential to generate $10 billion or more in annual sales by 2030 within the universe […]
Read More
Eli Lilly’s 2022 gains grow to 20% as it lays out plan for possibly the most successful drug ever
Eli Lilly’s obesity treatment tirzepatide has been granted “fast track” status by the Food and Drug Administration, which means it could win approval as early as late 2023. The drug, which was already approved to treat type 2 diabetes under the name Mounjaro in May, has the potential to be a blockbuster, analysts have said. […]
Read More
3 takeaways from our daily meeting: Stocks teeter, an oil trim, obesity drug fast track
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Thursday’s key moments. Stocks teeter Selling high, considering buying Quick mentions: LLY, COST 1. Stocks teeter Stocks swayed on Thursday after starting the week with sharp gains that puttered out by Wednesday. The […]
Read More
Stocks earning the major moves premarket: Peloton, Shell, Compass and extra
In this post PINS CAG PTON COMP TWTR SHEL-GB Abide by your favorite sharesGenerate Free ACCOUNT observe now Movie1:2401:24 News Update – Pre-Markets News Briefing Check out the providers building headlines ahead of the bell: Conagra (CAG) – The food stuff producer’s stock extra 2% in the premarket after it documented improved-than-expected quarterly financial gain […]
Read More
Here’s why Biogen’s promising Alzheimer’s drug data is also good news for Eli Lilly
We don’t own Eli Lilly exclusively for its potential Alzheimer’s treatment. However, we still find Biogen’s topline data to be very encouraging for Lilly. Source
Read More
2 takeaways from our daily meeting: What’s behind the bounce and Club stocks in the news
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. Market gets an oversold bounce Quick Club mentions: AAPL, LLY, EL 1. Market gets an oversold bounce U.S. stocks recovered after falling earlier Wednesday. Treasury yields pulled back from their highs and […]
Read More
2 takeaways from Thursday’s ‘Morning Meeting’: We want to buy on market weakness
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Thursday’s key moments. We have no choice but to buy Quick mentions: MRVL, LLY, NVDA, META 1. We have no choice but to buy Stocks slumped on Thursday, continuing their losing streak after […]
Read More